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Dendritic cell (DC)-based cellular immunotherapy is being
explored as a treatment modality for several malignancies, for viral
diseases and auto-immune disorders. More than four decades of
pre-clinical research on DC biology has cemented a strong foun-
dation for clinical application of DC-based clinical trials, which
already have been performed since the 1990s. Although some-
times met with limited patient success, clinical trials do yield better
understanding of the requirements for optimal DC-based therapy.
Recent advancements in the understanding of human DC biology
and subset characteristics now give rise to ample opportunities to
explore for a next generation of DC-based immunotherapy. This
Research Topic is focused on articles that can help understand-
ing the biology involved in DC antigen presentation, for future
DC-based immunotherapy.
Dendritic cells are professional antigen presenting cells
(APCs) that are particularly well endowed to elicit adaptive
immune responses, via the presentation and cross-presentation
of antigen-derived peptide/MHC complexes to T-lymphocytes.
These processes decide how the host interacts with its environ-
ment, and therefore can be a target for pathogen interruption. van
Montfoort et al. (1) provide an overview of cross-presentation
features and describe how the study of various viral pathogens
can elucidate anti-viral immune strategies. They further describe
how DC maturation is crucial in immunity against viruses and
how viruses may dampen this response to their own advantage.
Understanding these presentation pathways is pivotal to develop
effective DC-based immunotherapy.
Dendritic cell-based immunotherapy comes in two flavors.
Either DCs are cultured and manipulated ex vivo before infu-
sion, or endogenous DCs can be targeted in vivo. Concerning the
latter approach, local administration of long peptides has proved
effective in several diseases giving opportunity for further explo-
ration. Both Delamarre and Cohn (2) and Rosendahl Huber et al.
(3) discuss the requirements for improved antigen presentation,
providing considerations on CD4+ and CD8+ activation, choice
of antigen, and desired adjuvants. Delivering antigen to DCs is a
next hurdle to take.
Regarding antigen delivery, it matters to engage responsive
receptors, for these receptors can decide the intracellular path-
way of antigen routing and enzymatic processing. Antigens are
thereby directed toward assembly into peptide/MHC class I (cross-
presentation) or peptide/MHC class II complexes, and induction
of immunity or tolerance. Fehres et al. (4) describe the biology of
receptor-mediated uptake in the context of antigen presentation,
with special emphasis on C-type Lectin receptors. They further
discuss the possibilities to formulate antigen in order to pro-
vide receptor-directed antigen delivery. Another import route of
uptake involves the family of Fc receptors, which is discussed by
Platzer et al. (5). Here, the role of this receptor family is high-
lighted in antigen presentation with emphasis on the opposing
roles of activating and inhibiting Fc Receptor isoforms. Fur-
thermore, they underscore that mechanisms of antigen presen-
tation in mice are not always identical to the human pathways.
Thus, the need for more research on human DC biology is war-
ranted, for DC-vaccination strategies are still heavily based on
mouse-biology.
When designing a DC-based immunotherapy, it is relevant to
consider the subtype of DCs that one aims for. Boltjes and van Wijk
(6) present an overview of all phagocyte subsets that are present
throughout the human body in steady-state and under inflam-
matory conditions. They also emphasize the differences between
mouse and human cells, and review cell types that should be
considered for immunotherapy. Until recently, monocyte-derived
DCs (MoDCs) were used mostly in DC-therapy, for their rela-
tive ease to culture in large quantities ex vivo. But while MoDCs
can be found in human tissue under inflamed conditions, other
DC subsets are more prevalent overall and may be more specif-
ically endowed at stimulation of particular T-cell subsets, to be
explored in immunotherapy. One subset that was suggested to
be superior in CD8+ T-cell priming is the recently identified
BDCA-3+ (CD141+) DC, characterized by CLEC9A and XCR1
expression. Tullett et al. (7) highlight recent findings explaining
why these cells are effective at CD8+ T-cell priming and discuss
in vivo antigen targeting toward these DCs. Wimmers et al. (8)
also describe the use of naturally circulating mDCs and pDCs
for DC-based immunotherapy. They discuss the division of labor
between pDCs and mDCs and the clinical trials that are being per-
formed using these subsets. Interestingly, they highlight that mDCs
and pDCs work in synergy, supporting each other to enhance the
effector phase of the adaptive immune response. Based on this
observation, a next step in DC-based vaccination should include
a cocktail of mDCs and pDCs, or in vivo antigen targeting to both
subtypes.
Dendritic cells are often called “master regulators” of the
immune response. Besides firing up immune reactions, DCs
play an equally important role in the maintenance of periph-
eral tolerance, for example by dampening specific T-cell responses
or by inducing regulatory T-cell subsets. Loss of tolerance is
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FIGURE 1 | Schematic outline of the considerations to apply antigen cross-presentation research to the clinic, most readily by dendritic cell-based
immunotherapy.
of pivotal importance in auto-immune diseases as described
by Hopp et al. (9). Their review concerns the presentation of
self-antigen, which they discuss in the context of mechanisms
in tolerance induction, DC maturation status, DC uptake and
processing mechanisms, and tolerance-associated intracellular sig-
naling pathways. The regulation of DC function is also controlled
by metabolic pathways, as described by Everts and Pearce (10).
Recent advancements concerning regulation of DC metabolism
include the identification of key-proteins like PI3K, Akt, and
mTOR in DC function. The awareness that manipulation of DC
metabolic pathways changes DC function should be explored for
designing DC-based cellular therapy, especially since it may give
opportunity to steer toward more immunogenic or tolerogenic
consequences. This could be of upmost importance in the set-
ting of auto-immune diseases, anti-cancer, or graft-versus-host
therapy.
Plantinga et al. (11) finally discuss recent developments in DC-
therapy in the setting of allogeneic–hematopoietic cell transplan-
tations (HCT). Such transplantations are considered a last-resort
treatment for several malignancies of hematological origin. DCs
grown from the same donor background as the HCT are now
being explored for their potency to prevent cancer relapses early
after allogeneic HCT. The various considerations for such DC
vaccinations are discussed, such as the stem cell source, type of
tumor antigen, and vaccination strategy.
The breadth and quality of the work discussed in this Research
Topic underscores the strong translational push of DC research
toward clinical settings (Figure 1). Immunotherapy is now being
incorporated into standard cancer care, with antibody-based treat-
ments currently being at more advanced stages than cellular
therapies. The abundance of currently ongoing DC-based cel-
lular immunotherapy trials should benefit patient care in the
near future, as the roots for translational success are implanted
in well-established pre-clinical research settings.
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